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ABSTRACT 
Background Attendance at post-abortion follow-
up visits is poor, but little is known about factors 
affecting it.
Objective To assess the factors associated with 
non-compliance with post-abortion services and 
to evaluate differences in rates of attendance 
and intrauterine device (IUD) insertion according 
to the type of service provision.
Methods 605 women undergoing a first 
trimester medical termination of pregnancy 
(MTOP) and planning to use intrauterine 
contraception were randomised into two 
groups. Women in the intervention group 
(n=306) were booked to have IUD insertion 1–4 
weeks after the MTOP at the hospital providing 
the abortion, while women in the control 
group (n=299) were advised to contact their 
primary healthcare (PHC) centre for follow-up 
and IUD insertion.
Results In the intervention group, 21 (6.9%) 
women failed to attend the follow-up visit, 
whereas in the control group 67 (22.4%) women 
did not contact the PHC to schedule a follow-up 
(p<0.001). In both groups, non-attendance was 
associated with history of previous pregnancy 
and abortion. Not having an IUD inserted within 
3 months was significantly more common in 
the control group (73.6% (n=220)) than in the 
intervention group (9.2% (n=28), p<0.001). In 
the intervention group, predictive factors for not 
having an IUD inserted were anxiety, history of 
pregnancy and abortion. However, we identified 
no significant predictive factors in the control 
group.
Conclusions Factors predicting low compliance 
with post-MTOP follow-up are few. 
Comprehensive provision of abortion care and 
post-abortion services seems beneficial for 
minimising the loss to follow-up and delay in 
initiation of effective contraception.
Trial registration number NCT01223521;Results.
INTRODUCTION
Poor compliance with follow-up after 
termination of pregnancy (TOP) is a 
challenge in clinical care and in research 
studies. The reported rates of attend-
ance are commonly around 50%.1 2 Even 
though the need for routine follow-up 
after TOP is questionable and is not 
recommended by WHO and the Royal 
College of Obstetricians and Gynaecolo-
gists guidelines, it continues to be recom-
mended in some guidelines on induced 
abortion.3–5 Post-TOP care is useful for 
confirming the clinical outcome and 
encouraging contraceptive use.5 Initia-
tion of effective contraception shortly 
after TOP is advisable to minimise the 
risk of subsequent unwanted pregnancy. 
Yet the reported rates of non-attendance 
at planned intrauterine device (IUD) 
insertion visits have ranged from 12% to 
70%.6–9 
Several risk factors for the need for 
subsequent TOP have been character-
ised. These include young age, smoking 
and previous TOP or delivery, whereas 
choosing long-acting reversible contra-
ceptive methods lowers the risk.10 In addi-
tion, it has been shown that the longer the 
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delay in initiating contraception, the lower the rate of 
contraceptive use and the higher the risk of unplanned 
pregnancy.7 11
However, little is known about possible risk factors 
for poor compliance with follow-up after TOP. More 
flexible and individual means of follow-up,12 and even 
immediate initiation of long-acting reversible contra-
ceptive methods at the time of medical termination 
of pregnancy (MTOP), have recently been devel-
oped.8 13 14 Knowledge of these options is highly valu-
able in individualising post-TOP care. Being able to 
predict low compliance would be useful in targeting 
more intensified care, including contraceptive services, 
at those at greatest risk of dropping out.
Several factors related to healthcare provision may 
also affect use of post-TOP services. Previous studies 
have shown that initiation of intrauterine contraception 
can be hindered by misconceptions about its suitability 
in nulliparous women.15 Also, practical problems in 
reaching healthcare services, difficulties in contacting 
the healthcare provider to schedule further services, 
economic and even geographical and logistical issues, 
increase the risk of non-attendance.15 16 Centralising 
TOP and contraception services in a comprehensive 
manner has shown encouraging results in improving 
rates of attendance.8 17
This study is a secondary analysis of a large 
randomised controlled trial (RCT) assessing the effect 
of early IUD provision as part of a first trimester TOP 
service on the need for subsequent TOP.18 In the RCT 
we found that in the first year after TOP, this need 
was significantly reduced (2.4% vs 5.4%, p=0.038) 
among women randomised to early provision of an 
IUD, in comparison with routine service delivery. In 
the present secondary analysis, we assessed the risk 
factors for non-compliance both in contacting health-
care providers for scheduled post-TOP care and for 
initiation of planned intrauterine contraception during 
the 3 months after MTOP.
METHODS
We conducted a RCT assessing the long-term effects 
of routine provision of IUDs as a part of TOP services 
among women (n=748), requesting either medical or 
surgical first trimester TOP. The study was carried out 
in collaboration with the Department of Obstetrics 
and Gynaecology, Helsinki University Hospital and 
the Centralised Family Planning, Department of Social 
Services and Health Care, City of Helsinki, between 
October 2010 and February 2018.18
Inclusion criteria were age ≥18 years, pregnancy 
≤12 weeks of gestation, residence in the City of 
Helsinki and interest in intrauterine contraception 
after TOP. Women with contraindications to intra-
uterine contraception, such as uterine anomaly, 
acute genital infection or a cervical screening result 
requiring surgical intervention, were excluded. Rando-
misation was accomplished by a computer-assisted 
permuted-block method. The investigators did not 
participate in randomisation, which was done before 
the study started. The group assignments were kept 
in sealed envelopes, which were opened by the study 
nurse after informing and recruiting the women.
All procedures relating to induced abortion were 
carried out according to current Finnish national 
guidelines on TOP.3 Women in the intervention group 
received an IUD, either a LNG 52 mg IUD (Mirena) or 
a copper IUD (Nova-T), both manufactured by Bayer 
Ag, Turku, Finland, at the hospital at the time of surgical 
TOP or at a scheduled follow-up visit 1–4 weeks after 
MTOP. All women choosing MTOP were encouraged 
to use oral contraceptives for interval contraception 
until the IUD insertion and were provided with a 
3-month initiation package of pills to be started imme-
diately after MTOP.
Women in the control group were advised to attend 
their primary healthcare (PHC) centre for a follow-up 
visit according to the national guideline for serum 
human chorionic gonadotrophin (hCG) measurement 
and a nurse appointment,3 as well as for IUD insertion.
Women in the intervention group were invited to 
a study nurse visit at the hospital 3 months after the 
TOP. Women in both groups were offered a free-of-
charge gynaecological check-up visit after 1 year.
All participants received a questionnaire at base-
line and another at 3 months, assessing quality of life, 
anxiety, sexuality and experienced state of health. 
Anxiety was measured on the State-Trait Anxiety 
Inventory (STAI), using the 20-item State subscale.19 
A score >40 is generally considered indicative of clin-
ically relevant anxiety.20 21
In the primary RCT we assessed the effects of early 
routine provision of IUD contraception in preventing 
subsequent TOPs. In addition, the study allowed us to 
assess effectiveness of the two different means of service 
provision—namely, the current practice of providing 
post-abortion care at the PHC centre, compared with 
a comprehensive approach in which IUDs are inserted 
at the same unit that provides the TOP.
In the present analysis, of the 748 study participants 
we focus on the 605 women who chose medical TOP, as 
the majority of women choosing surgical TOP received 
the IUD during the procedure. Thus, there were 306 
women in the intervention group and 299 women in 
the control group (figure 1). Table 1 summarises the 
background characteristics of the participants. There 
were no significant demographic differences between 
the groups.
In the intervention group, the follow-up visit was 
scheduled at the time of the TOP. A reminder text 
message (SMS) was sent before this appointment. When 
patients failed to attend, two additional attempts were 
made for rebooking, either by phone call or by SMS.
In the control group, data on contacting and 
visiting the PHC centre were gathered from the data-
bases of the City of Helsinki PHC centre. Attendance 
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for follow-up was defined as attending a scheduled 
PHC appointment or having a serum hCG measured 
and contacting the PHC centre at least by telephone 
within 1 month after the TOP. In accordance with 
national guidelines, a pelvic examination was not 
regarded as necessary.
Figure 1 Study flow chart. IUD, intrauterine device; PHC, primary healthcare centre.
Table 1 Characteristics of 605 study participants undergoing first trimester medical termination of pregnancy and planning IUD for 
post-TOP contraception
Variable
Intervention group
n=306 (%)
Control group
n=299 (%)
Total
n=605 P values
Age (years); median (IQR) 27 (22 to 32) 27 (23 to 33) 27 (22 to 33) 0.389
Duration of pregnancy (days); median (IQR) 56 (48 to 64) 54 (47 to 63) 55 (47 to 63) 0.103
Regular smoking 153 (50.0) 153 (51.2) 306 (50.6) 0.773
Regular use of alcohol 231 (75.5) 236 (78.9) 467 (77.2) 0.313
History of drug abuse 7 (2.3) 12 (4.0) 19 (3.1) 0.224
History of pregnancy* 208 (68.2) 200 (66.7) 408 (67.4) 0.688
History of TOP 139 (45.4) 120 (40.1) 259 (42.8) 0.189
History of delivery 148 (48.4) 134 (44.8) 282 (46.6) 0.382
Marital status 0.242
  Married 57 (18.6) 42 (14.0) 99 (16.4)
  Cohabiting 83 (27.1) 78 (26.1) 161 (26.6)
  Single 166 (54.2) 179 (59.9) 345 (57.0)
Diagnosis of a psychiatric condition 54 (17.6) 40 (13.4) 94 (15.5) 0.147
STAI index >40 at baseline 170/300 (56.7) 169/280 (60.4) 339/580 (58.4) 0.367
Diagnosis of a somatic condition 123 (40.2) 112 (37.5) 235 (38.8) 0.490
History of STD 117 (38.2) 106 (35.5) 223 (36.9) 0.478
Body mass index (kg/m2); median (IQR) 23 (21 to 25) 23 (21 to 26) 23 (21 to 26) 0.658
*Includes all previous pregnancies, regardless of the outcome, before index pregnancy.
IUD, intrauterine device; STAI, State-Trait Anxiety Inventory; STD, sexually transmitted disease; TOP, termination of pregnancy.
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Patient involvement
The study participants were not involved in designing 
the study.
Statistical analysis
Statistical analyses were performed with SPSS 
version 24.0 (IBM Corp, Armonk, New York, USA). 
In analysing rates of attendance and IUD insertions, 
logistic regression was used to calculate ORs with a 
95% CI. Student’s t-test was used in comparison of 
continuous variables, for which the mean values and 
SD are reported.
RESULTS
Non-compliance with follow-up: intervention group
In the intervention group, 21/306 (6.9%) women did 
not attend the planned follow-up visit or receive an 
IUD despite phone calls, SMS messages and rebook-
ings. Altogether 285 (93.1%) women attended the first 
follow-up visit 1–4 weeks after TOP.
Table 2 shows non-attendance at follow-up in both 
the intervention and control groups according to 
various background factors. Significant predictors of 
non-attendance at the first follow-up visit among the 
intervention group were smoking (9.8% (n=15) of 
smokers vs 3.9% (n=6) of non-smokers, OR=2.66 
(95% CI 1.01 to 7.06), p=0.049), history of drug 
abuse (28.6% (n=2) vs 6.4% (n=19), OR=5.90 (95% 
CI 1.07 to 32.41), p=0.041), history of pregnancy 
(9.6% (n=20) vs 1.0% (n=1), OR=10.16 (95% CI 
1.34 to 76.84), p=0.025), history of TOP (12.2% 
(n=17) vs 2.4% (n=4), OR=5.68 (95% CI 1.86 to 
17.30), p=0.002) and STAI score >40 indicating clin-
ically relevant anxiety (8.8% (n=15) vs 2.2% (n=3), 
OR=4.10 (95% CI 1.16 to 14.47) p=0.028). The 
mean number of previous TOPs was significantly 
higher in women not attending the follow-up visit 
(1.33 (SD 1.16)) than in those attending the visit (0.68 
(SD 0.96), p=0.003). However, the difference was not 
significant when the number of all previous pregnan-
cies was considered (1.93 (SD 2.10) vs 2.67 (SD 2.24), 
p=0.120).
In multivariate analysis, smoking remained signifi-
cant in predicting non-attendance when adjusted for 
age, alcohol consumption and drug abuse. Previous 
pregnancies remained a significant predictor for low 
attendance when controlled for age, smoking, alcohol 
Table 2 Non-attendance at follow-up visit after first trimester medical termination of pregnancy
Both groups (n=605) Intervention group (n=306) Control group (n=299)
OR (95% CI) P values OR (95% CI) P values OR (95% CI) P values
Randomisation group 7.03 (4.25 to 11.63) <0.001 N/A N/A N/A N/A
Regular smoking 1.38 (0.92 to 2.05) 0.116 2.66 (1.01 to 7.06) 0.049 1.18 (0.73 to 1.91) 0.494
Regular use of alcohol 0.80 (0.51 to 1.27) 0.343 0.80 (0.30 to 2.14) 0.654 0.68 (0.38 to 1.20) 0.179
History of drug abuse 2.36 (0.91 to 6.14) 0.077 5.90 (1.07 to 32.41) 0.041 1.40 (0.43 to 4.52) 0.575
Diagnosis of a psychiatric condition 1.15 (0.68 to 1.96) 0.599 2.53 (0.97 to 6.61) 0.058 1.05 (0.52 to 2.10) 0.899
STAI index >40 1.70 (1.10 to 2.63) 0.017 4.10 (1.16 to 14.47) 0.028 1.41 (0.84 to 2.35) 0.194
History of cervical screening abnormality 1.55 (0.81 to 2.96) 0.190 1.73 (0.48 to 6.29) 0.403 1.86 (0.79 to 4.39) 0.154
History of
STD
0.90 (0.60 to 1.36) 0.625 1.23 (0.50 to 3.01) 0.652 0.87 (0.53 to 1.44) 0.582
History of pregnancy* 2.46 (1.51 to 4.01) <0.001 10.16 (1.34 to 76.84) 0.025 2.38 (1.37 to 4.14) 0.002
History of TOP 1.96 (1.32 to 2.93) 0.001 5.68 (1.86 to 17.30) 0.002 1.97 (1.21 to 3.21) 0.006
History of delivery 1.43 (0.96 to 2.12) 0.080 2.25 (0.88 to 5.75) 0.089 1.46 (0.90 to 2.36) 0.124
Marital status
  Single (reference category) 1.00 – 1.00 – 1.00 –
  Cohabitating 0.98 (0.62 to 1.55) 0.932 0.51 (0.16 to 1.59) 0.245 1.27 (0.73 to 2.21) 0.395
  Married 0.65 (0.36 to 1.20) 0.170 0.37 (0.08 to 1.65) 0.191 0.91 (0.44 to 1.88) 0.803
Age group (years)
  <20 (reference category) 1.00 – 1.00 – 1.00 – 
  20–24 1.14 (0.47 to 2.77) 0.781 0.27 (0.06 to 1.32) 0.106 1.92 (0.58 to 6.36) 0.289
  25–29 1.16 (0.47 to 2.89) 0.746 0.70 (0.17 to 2.99) 0.634 1.36 (0.40 to 4.61) 0.623
  30–34 1.18 (0.46 to 3.00) 0.728 0.32 (0.06 to 1.70) 0.180 2.07 (0.59 to 7.20) 0.253
  35–39 1.36 (0.52 to 3.56) 0.535 0.72 (0.15 to 3.58) 0.692 1.68 (0.47 to 6.06) 0.427
  ≥40 1.10 (0.32 to 3.53) 0.316 0.000 1.000 1.77 (0.40 to 7.93) 0.454
*Includes all previous pregnancies, regardless of the outcome, before the index pregnancy.
STAI, State-Trait Anxiety Inventory; STD, sexually transmitted disease; TOP, termination of pregnancy. 
group.bmj.com on October 10, 2018 - Published by http://srh.bmj.comDownloaded from 
Pohjoranta E, et al. BMJ Sex Reprod Health 2018;44:278–285. doi:10.1136/bmjsrh-2018-200098282
Research
consumption and drug abuse. However, a previous 
TOP was a significant predictor for poor compliance 
when controlled for age and previous pregnancies.
Non-compliance with follow-up: control group
In the control group 67 (22.4%) women did not contact 
the PHC centre to schedule a follow-up. One hundred 
and two (34.1%) women contacted the PHC centre but 
opted out of follow-up by telephone contact or by a visit.
Non-attendance at any post-TOP check (hCG 
measurement and/or a contact by phone or at the 
PHC) was significantly more common in women 
with previous pregnancies (40.2% (n=80) vs 22.0% 
(n=22), OR=2.38 (95% CI 1.37 to 4.14), p=0.002) 
and previous TOPs (43.3% (n=52) vs 27.9% (n=50), 
OR=1.97 (95% CI 1.21 to 3.21), p=0.006). In multi-
variate analysis, previous pregnancies remained signif-
icant when controlled for age, smoking and previous 
TOPs. Non-attendance was also significantly associ-
ated with a higher number of previous pregnancies 
(mean 2.01 (SD 1.97) vs 1.60 (SD 1.78), p=0.44) 
and previous TOPs (mean 0.86 (SD 1.09) vs 0.46 (SD 
0.74), p<0.001).
Non-compliance with IUD insertion
In the intervention group 28 (9.2%) and in the control 
group 220 (73.6%) women did not have an IUD 
inserted during the first 3 months after MTOP. The 
difference between the groups was highly significant 
(OR=27.65 (95% CI 17.35 to 44.06), p<0.001). Odds 
ratios of not having an IUD inserted during the first 3 
months, according to various background factors, are 
presented in table 3.
In the intervention group, 74 (24.2%) women had 
not received an IUD as prescribed in the protocol 
(within 4 weeks) after the TOP. At 3 months after the 
TOP, the number of women who had not had an IUD 
inserted was 28 (9.2%). Seven women refused IUD 
insertion at the follow-up visit and chose another 
contraceptive method instead. Women with previous 
Table 3 Odds of not receiving an IUD during 3 months after TOP in women undergoing a first trimester termination of pregnancy and 
planning IUD contraception
Both groups (n=605) Intervention group (n=306) Control group (n=299)
OR (95% CI) P values OR (95% CI) P values OR (95% CI) P values
Randomisation group 27.65 (17.35 to 44.06) <0.001 N/A N/A N/A N/A
Regular smoking 1.13 (0.82 to 1.57) 0.450 1.61 (0.73 to 3.57) 0.238 1.03 (0.62 to 1.72) 0.911
Regular use of alcohol 1.20 (0.81 to 1.77) 0.368 0.97 (0.40 to 2.39) 0.950 1.15 (0.62 to 2.13) 0.663
History of drug abuse 2.03 (0.80 to 5.11) 0.135 4.20 (0.78 to 22.73) 0.096 1.08 (0.29 to 4.10) 0.909
Diagnosis of a psychiatric condition 0.79 (0.50 to 1.24) 0.302 1.64 (0.66 to 4.07) 0.288 0.71 (0.35 to 1.46) 0.350
Diagnosis of a somatic condition 0.76 (0.55 to 1.07) 0.114 0.81 (0.36 to 1.82) 0.612 0.68 (0.40 to 1.14) 0.144
STAI index >40 at baseline 1.24 (0.88 to 1.74) 0.215 2.60 (1.01 to 6.71) 0.048 0.91 (0.53 to 1.59) 0.748
STAI index >40 at 3 months 1.33 (0.83 to 2.14) 0.239 2.70 (0.71 to 10.36) 0.147 0.78 (0.40 to 1.53) 0.471
History of cervical screening abnormality 1.10 (0.62 to 1.97) 0.745 0.75 (0.17 to 3.32) 0.700 2.53 (0.73 to 8.77) 0.142
History of colposcopy 0.86 (0.41 to 1.79) 0.680 1.26 (0.27 to 5.78) 0.767 0.89 (0.27 to 2.93) 0.852
History of pregnancy* 1.28 (0.90 to 1.81) 0.172 4.26 (1.25 to 14.46) 0.020 1.31 (0.77 to 2.24) 0.320
History of TOP 1.32 (0.95 to 1.82) 0.101 4.07 (1.67 to 9.88) 0.002 1.64 (0.95 to 2.83) 0.074
History of delivery 0.81 (0.59 to 1.12) 0.208 1.26 (0.58 to 2.74) 0.564 0.68 (0.41 to 1.14) 0.141
Marital status
  Single
  (reference category)
1.0 – 1.00 – 1.00 – 
  Cohabitating 0.55 (0.34 to 0.88) 0.012 0.62 (0.20 to 1.92) 0.407 0.52 (0.25 to 1.07) 0.074
  Married 0.71 (0.49 to 1.04) 0.082 0.64 (0.24 to 1.68) 0.365 0.65 (0.36 to 1.18) 0.153
Age group (years)
  <20 (reference category) 1.0 – 1.00 – 1.00 – 
  20–24 1.23 (0.60 to 2.53) 0.566 0.42 (0.10 to 1.82) 0.245 2.01 (0.66 to 6.14) 0.221
  25–29 1.69 (0.82 to 3.51) 0.158 1.06 (0.26 to 4.24) 0.939 2.11 (0.68 to 6.59) 0.197
  30–34 0.86 (0.40 to 1.84) 0.695 0.67 (0.15 to 2.93) 0.591 0.79 (0.26 to 2.46) 0.689
  35–39 1.37 (0.62 to 3.00) 0.434 0.53 (0.10 to 2.87) 0.460 1.63 (0.49 to 5.47) 0.424
  ≥40 1.07 (0.41 to 2.83) 0.889 0.000 1.00 1.31 (0.31 to 5.53) 0.714
*Includes all previous pregnancies, regardless of the outcome, before the index pregnancy.
IUD, intrauterine device; STAI, State-Trait Anxiety Inventory; TOP, termination of pregnancy. 
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pregnancies were less likely to receive an IUD within 
3 months (12.0% (n=25) vs 3.1% (n=3), OR=4.26 
(95% CI 1.25 to 14.46), p=0.020). A similar result 
was seen in women with previous TOPs (15.1% 
(n=21) vs 4.2% (n=7), OR=4.07 (95% CI 1.67 to 
9.88), p=0.002), which was no longer significant 
when controlled for previous pregnancies (p=0.057). 
However, the differences remained significant when 
controlled for age, smoking and alcohol consumption.
In the control group, no background factors were 
significantly associated with not receiving an IUD. 
During the first 3 months’ follow-up after MTOP, 
69.4% (n=93) of parous women and 77.0% (n=127) 
of nulliparous women did not receive an IUD. Women 
with a past history of TOP had a higher rate of non-use 
of IUD (79.2% (n=95)) than women with no history 
of TOP (69.8% (n=125)), but the difference was 
not statistically significant (OR=1.64 (95% CI 0.95 
to 2.83), p=0.074). Women with clinically relevant 
anxiety levels at baseline had rates of IUD insertion 
similar to those with lower levels of anxiety (74.0% 
(n=125) vs 75.7% (n=84)). Of the women reporting 
previous drug abuse, 75% (n=9) did not receive an 
IUD during 3 months after MTOP.
Seventy-one women in the control group received 
an IUD from the PHC centre during the 3 months after 
MTOP. In addition, four women had an IUD inserted 
by a private doctor and another four women received 
an IUD at the hospital rather than at the PHC centre 
during the 3 months, in contrast to the study protocol; 
three at the time of uterine evacuation of retained 
products and one at a check-up following a TOP-re-
lated uterine infection.
DISCUSSION
Main findings
Poor compliance with post-TOP care was clearly 
observed in this study. The attendance rates were 
notably low among the women treated according to 
normal clinical procedure (control group) even though 
their management followed national guidelines. This 
is of particular significance, as these women belonged 
to a specially motivated group volunteering for a 
randomised trial and had expressed their interest in 
IUD contraception. We find few obvious risk factors 
predicting this low compliance. However, when all the 
participants were considered, non-attendance at the 
first follow-up was associated with clinically relevant 
levels of anxiety, as well as history of previous preg-
nancies and/or TOP.
One of our goals was to compare the standard 
approach to providing post-TOP initiation of intra-
uterine contraception with comprehensive easier access 
to IUD insertion and follow-up visits. The study findings 
clearly showed that providing MTOP and IUD insertion 
with minimal delay in a comprehensive manner results 
in significantly higher attendance for follow-up and rates 
of IUD initiation.
In the intervention group, all women who attended 
the follow-up and who were willing to have an IUD, 
received it within 3 months. Seven women chose 
another method instead. Thus, factors affecting IUD 
use in this group are essentially those associated with 
non-attendance. As the attendance rate in this group 
was exceptionally high (93%) even though several 
attempts were made to contact the women if necessary, 
the non-attenders represent a very select and non-com-
pliant proportion of women.
In the control group, the rate of attendance was 
similar to that reported previously.1 2 This group 
represented women in a ‘normal’ setting, with the only 
difference from the base population being participa-
tion in the study. In this group, non-attendance could 
be predicted only by a history of pregnancy and/or 
TOP. It is noteworthy that only 40% of the women 
attending the follow-up (by telephone or at a visit) 
received an IUD during the first 3 months (and 66% 
during the first year). Among women who did not 
attend PHC center follow-up, the rate of IUD use at 
3 months was 7.8% (n=8) and half of these women had 
received the IUD at the hospital during a visit related 
to a diagnosed or suspected complication. We found 
no significant background factors predicting failure to 
have an IUD inserted. This finding reflects inefficacy 
of decentralised post-TOP services and contraceptive 
care.
Prescribing oral contraceptives after TOP is often 
considered as a ‘bridging method’, allowing more time 
to arrange an IUD insertion. In light of these findings, 
the idea of bridging does not seem to work in most 
women as only a quarter of the women (26%) in the 
control group received an IUD within 3 months. This 
is at least partly independent of the women’s compli-
ance and initiative and might be caused by factors such 
as shortage of physicians skilled in IUD provision, 
difficulty in scheduling or unnecessary delay in waiting 
for menstrual periods.
Strengths and limitations
The randomised structure of this study is its strength. 
However, limitations are that the findings are not 
directly applicable to all healthcare systems, as poli-
cies on where, at what cost and by whom, contra-
ceptive services are provided differ greatly. Further-
more, all women participating in the study were by 
definition interested in IUD contraception, so the 
study population may not be representative of all 
women undergoing TOP. The women in the inter-
vention group were given individualised service: 
they were flexibly rebooked for missed appointments 
and contacted several times if they failed to attend. 
In the real-life situation with a large flow of patients 
and fixed appointment schedules it may be impos-
sible to provide such care. The exceptionally high 
rate of attendance in the intervention group may 
therefore give an optimistic perception of the effect 
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of comprehensive services. It is noteworthy that this 
study was initiated in 2010 and attitudes, practices 
and recommendations regarding IUD use, particularly 
in younger and nulliparous women, have changed 
over the past few years.22–25
CONCLUSIONS
A key finding of this study is that there are few risk 
factors for non-compliance with post-TOP care. This is 
in contrast with the risk factors for the need of subse-
quent TOP.10 Thus, comprehensive provision of both 
MTOP and post-TOP contraception (including IUD 
provision) is likely to be beneficial.
Home testing for TOP outcome is being established 
as standard of care, and increasing possibilities for 
initiation of intrauterine contraception without delay 
following TOP are emerging.12 The findings of this 
study can be of value in individualising post-TOP care 
and contraception planning, as well as in designing 
comprehensive TOP care. Attendance for post-TOP 
care is generally low and predicting non-attendance 
is difficult. Centralising TOP with post-TOP IUD 
services and setting up easily accessed, one-visit clinics 
is likely to lead to better overall rates of attendance 
and post-TOP IUD initiation.
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